Key Takeaways
- Personalized mRNA vaccines reduced melanoma recurrence and death risk by 49% at five-year follow-up.
- Each vaccine targets up to 34 unique markers from a patient’s specific tumor mutations.
- Moderna and Merck are testing similar vaccines against lung, bladder, and kidney cancers.
Innovative Approach to Cancer Treatment
A customized mRNA vaccine has shown significant potential in providing sustained protection against aggressive skin cancer, specifically melanoma, over a five-year period. In a Phase 2 trial, patients who received the experimental mRNA vaccine alongside standard immunotherapy experienced a nearly 50 percent reduction in the risk of cancer recurrence or death compared to those who received immunotherapy alone.
Jointly developed by Moderna and Merck, the mRNA vaccine named intismeran autogene (also referred to as mRNA-4157 or V940) targets specific mutations found in a patient’s tumor DNA, ensuring a tailored approach to treatment. Full data is expected to be shared at an upcoming medical conference, and a Phase 3 trial has already completed enrollment.
Details of the Trial
The Phase 2 trial included 157 patients diagnosed with stage 3 or stage 4 melanoma, with all participants having undergone surgery yet facing a high risk of cancer recurrence. Every individual received Keytruda (pembrolizumab), an immunotherapy drug that inhibits cancer cells’ ability to evade the immune response. Patients were randomized to receive either both treatments or Keytruda alone, with 107 receiving the personalized mRNA vaccine.
The vaccine’s customization involves analyzing each tumor for up to 34 unique mutations. The generated vaccine then instructs healthy cells to create markers based on these mutations, enabling T cells to recognize and destroy the cancer cells.
Long-Term Efficacy
Data from earlier checkpoints corroborated the recent findings. At the two-year mark, 22 percent of patients who received both Keytruda and the mRNA vaccine experienced recurrence or death, compared to 40 percent in the Keytruda-only group, signifying a 44 percent risk reduction. The five-year follow-up confirmed a 49 percent reduction in risk across both the three- and five-year periods.
Side effects from the treatment remained manageable. Patients reported fatigue, injection site pain, and chills, but no significant differences in side effects were observed between the two groups.
Industry Perspectives
Kyle Holen, a senior vice president at Moderna, emphasized the potential for long-term benefits from the combination of the mRNA vaccine and Keytruda for high-risk melanoma patients. Moderna is also exploring mRNA vaccines for other cancers, with eight ongoing Phase 2 and Phase 3 trials for conditions such as lung, bladder, and kidney cancers.
Marjorie Green, a senior vice president at Merck, described the five-year data as a significant milestone and expressed excitement for the forthcoming late-stage data from their collaborative program, which aims to address various unmet needs in cancer treatment.
Broader Context
These promising developments come amid a challenging environment for mRNA technology. Political figures have raised concerns regarding the safety and efficacy of mRNA vaccines, particularly in relation to COVID-19, leading to the cancellation of substantial federal grants for mRNA research.
Conclusive assessments of the mRNA cancer vaccine’s effectiveness will require the publication of complete trial data. The ongoing research indicates a strong potential for personalized mRNA vaccines to transform cancer treatment in the future.
The content above is a summary. For more details, see the source article.